Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.
This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]
Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]
Paris (France), July 31, 2019 – 7.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Paris (France), September 29, 2020 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]
Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]
DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]
Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]
July 3, 2020 – 6:00 pm CEST Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]
Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells […]
Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]
Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]
The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022 Paris […]
The Extraordinary General Meeting will be held on June 19, 2020 on the second call Paris (France), May 29, […]
Paris (France), May 27, 2020 – 8.45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), Mai 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), April 27, 2020 – 7.00 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
Paris (France), May 7, 2020 – 7:30 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
Cash position of €5.7 million at December 31, 2019, combined with $6.6 million from new agreement with Acrotech, provide extended […]
This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology $6.6m […]
Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
The Annual General Meeting will be held on May 29, 2020 Paris (France), March 27, 2020 – 8:30 pm CET […]
Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), January 20, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Dowload the press release
Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]
In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]
The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to […]
(in French only) Watch the interview
Settlement agreement fully resolves long-lasting litigation between the parties and all related proceedings Settlement terms have no impact on Onxeo’s […]
Read the article in Le Quotidien du Médecin (in French)
Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Combination patent to be granted in the U.S. until 2036 Paris (France), November 4, 2019 – 5:45 pm CEST – […]
The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]
Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]
This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]
Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]
Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]
Read more on BFM Bourse (in French)
Read the article in Les Echos (in French)
Read the article in Cancer Research News
Read the article in La Tribune (in French)
Read the article on clinicalleader.com
Watch the interview on La Bourse et la Vie.com (in French)